BlackRock Health Sciences Term Trust Declares Monthly Dividend of $0.18 (NYSE:BMEZ)

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a monthly dividend on Thursday, September 12th, NASDAQ reports. Stockholders of record on Tuesday, October 15th will be paid a dividend of 0.176 per share on Thursday, October 31st. This represents a $2.11 annualized dividend and a dividend yield of 13.37%. The ex-dividend date is Tuesday, October 15th.

BlackRock Health Sciences Term Trust has raised its dividend by an average of 20.7% annually over the last three years.

BlackRock Health Sciences Term Trust Stock Up 0.5 %

BMEZ traded up 0.08 during midday trading on Friday, hitting 15.79. The stock had a trading volume of 170,600 shares, compared to its average volume of 271,406. The business has a fifty day moving average of 15.85 and a 200 day moving average of 15.50. BlackRock Health Sciences Term Trust has a 1 year low of 12.93 and a 1 year high of 16.59.

Insider Transactions at BlackRock Health Sciences Term Trust

In other news, major shareholder Saba Capital Management, L.P. bought 15,455 shares of the stock in a transaction on Thursday, September 19th. The stock was bought at an average cost of 16.14 per share, for a total transaction of 249,443.70. Following the completion of the purchase, the insider now directly owns 20,601,568 shares in the company, valued at approximately 332,509,307.52. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have bought a total of 54,554 shares of company stock valued at $871,545 in the last 90 days.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.